Wed, Jul 30, 2014, 11:02 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Amarantus Bioscience Holdings, Inc Message Board

biotechpicklist 166 posts  |  Last Activity: 3 hours ago Member since: Sep 10, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • biotechpicklist biotechpicklist 3 hours ago Flag

    helpme hanna I can see what you are trying to say about raising money but nobody knows the future it depends on many things. For instance think of partnerships. if RXI-109 can partner out the other pipeline candidates then it won't need to raise money. THat's because typically big pharma companies pay the upfront costs and development of the trials to be run. I'm not saying that RXI won't ever have to sell more shares for money but there is a possibility they won't need to short term if they can obtain partnerships.

    Sentiment: Strong Buy

  • Reply to

    TKMR stronger than ARWR

    by kaceaz 7 hours ago
    biotechpicklist biotechpicklist 3 hours ago Flag

    ARWR has the upper hand here because it is already testing a phase 2a trial with hepatitis B. Tekmira hasn't even started a phase 1 yet in hepatitis B. So phase 2 validation on delivery technology is closer with ARWR. Tekmira is still way off from proving their technology in a phase 2 trial.

    Sentiment: Strong Buy

  • Reply to

    Just can't fathom Lack of interest for RXII

    by biotechpicklist Jul 29, 2014 8:17 PM
    biotechpicklist biotechpicklist Jul 29, 2014 10:36 PM Flag

    well I like a lot of them on my website. INO is good, RXII, INO, CTIX, AMBS

    Sentiment: Strong Buy

  • Reply to

    Just can't fathom Lack of interest for RXII

    by biotechpicklist Jul 29, 2014 8:17 PM
    biotechpicklist biotechpicklist Jul 29, 2014 10:35 PM Flag

    Also the share price traded at .08 cents per share before it ran up to .33 cents per share on OTC. Then it came back down to .13 or .19 before the reverse split. can't remember well now lol!

    Sentiment: Strong Buy

  • Reply to

    Premature Conclusions?

    by mitchpit11 Jul 29, 2014 8:43 PM
    biotechpicklist biotechpicklist Jul 29, 2014 8:50 PM Flag

    people, excuse me some smart investors aren't as gullible to listen to AF and other bearish drivel. As you have mentioned the study didn't even use the maximum dosage level.

    going from 2 mg/mg and 4 mg/kg to 8 mg/kg makes a huge difference because from 4 to 8 you are effictively doubling the dosage which is huge. Secondly the data monitor has concluded for the company to advance to cohort 3 , if the trial was a failure as bearish articles suggest then the company would scrap cohort 3 completely. Also the phase 2 trial will separate the blood biomarker analysis at four time points in the study.

    Sentiment: Strong Buy

  • Then again many good companies sat at low prices before booming, like Google at $7 per share, and Apple at $7 per share. I'm locked and loaded with a huge position in RXII , and I don't think people grasp the huge potential here. Only us long term investors do but the market is oblivious.

    43 million planned surgeries as of 2012 by now it probably has increased. There are "Zero" I repeat "Zero" FDA approved drugs for scarring. IF RXI-109 makes it to market it will be the first anti-scarring drug to be ever approved by the FDA, unless Excaliard makes it there first. (but haven't heard anything from them about a phase 3 trial......) But I'm happy and will be as patient as needed until platform is validated!

    Sentiment: Strong Buy

  • Reply to

    ALNY issued new delivery patent...

    by rmsacc Jul 28, 2014 10:58 AM
    biotechpicklist biotechpicklist Jul 28, 2014 8:13 PM Flag

    Also if anyone else noticed the CEO said he saw some of the picture results. the trial is still double-blinded but the CEO said he was happy with what he saw. Obviously we don't know which is placebo or which is RXI-109 but I would think RXI-109 would be the one greatly reducing the scar, and the placebo not so much.

    Sentiment: Strong Buy

  • Reply to

    Arrowhead CEO will be on CNBC This afternoon

    by ssheykhrez Jul 28, 2014 4:13 PM
    biotechpicklist biotechpicklist Jul 28, 2014 4:41 PM Flag

    anti scarring market = minimum revenue $1 billion , maximum revenue $5 billion
    if RXI-109 phase 2 shows positive results then it has

    PVR = orphan disease small money there but orphan designation

    Macular degeneration both dry and wet = Using both VEGF and RXI-109 knockdown disease, and heal tissue = $5 to $6 billion market

    If RXI-109 proves itself then it can be used also for Liver Fibrosis = $5 to $6 billion dollars

    Retinoblastoma is eye cancer in children. Orphan drug , and company has picked the targeted gene i beleive it is MDM 2 something like that.

    So if the results in one to 2 months pan out in RXI-109 in hypertrophic scars then huge potential!

    Sentiment: Strong Buy

  • Reply to

    Wow , look @ the $14 call options for Aug.

    by ssheykhrez Jul 28, 2014 3:48 PM
    biotechpicklist biotechpicklist Jul 28, 2014 4:15 PM Flag

    Must be good results CEO on Fast Money tonight at 5 p.m. est time

    Sentiment: Strong Buy

  • Reply to

    Arrowhead CEO will be on CNBC This afternoon

    by ssheykhrez Jul 28, 2014 4:13 PM
    biotechpicklist biotechpicklist Jul 28, 2014 4:15 PM Flag

    yep tonight t 5 p.m. est time on Fast money. I think it is looking good for CEO to be on Fast money, results must be good. For those looking for another good RNAi play I recommend RXII trading at $2.50 per share.

    Sentiment: Strong Buy

  • biotechpicklist biotechpicklist Jul 27, 2014 9:51 PM Flag

    I agree with you autumn9991

    Sentiment: Strong Buy

  • biotechpicklist biotechpicklist Jul 27, 2014 9:51 PM Flag

    To be honest only 1 to 2 months left. My guess is September since that's when institutions are back from summer break. Also RXII is expected to present September 8th, 2014 at Rodman And Renshaw. Make sense to post results in morning prior to presentation because then at presentation they can show the pictures so investors see the difference between hypertrophic scars treated with placebo and then those treated with RXI-109.

    Sentiment: Strong Buy

  • Reply to

    Leroy Young, M.D. Scientific Advisory Board

    by wildbullus Jul 26, 2014 6:50 PM
    biotechpicklist biotechpicklist Jul 27, 2014 2:30 PM Flag

    Dr. Campochiaro was one of the first investigators along with others that figured out VEGF as a target for eye diseases. He has written 300 peer reviewed articles on VEGF for eye diseases, and for him to join up with RXI pharmaceuticals is a smart move IMO. He probably sees what I see the ability for VEGF knockdown for underlying treatment of macular degeneration, along with RXI-109 for reduction of tissue damage for improved vision. so VEGF and RXI-109 put together could knock out 2 birds with one stone so to speak.

    Sentiment: Strong Buy

  • biotechpicklist biotechpicklist Jul 27, 2014 12:44 PM Flag

    no problem

    Sentiment: Strong Buy

  • biotechpicklist biotechpicklist Jul 26, 2014 10:08 PM Flag

    so RXII will use rxRNA to deliver compounds systemically. A little more advanced than local delivery but good to see the company is working on systemic delivery as well. All in due time!

    Sentiment: Strong Buy

  • sd-rxRNA delivers RNAi locally through the skin and tissue, so many on this board have been asking what about systemic delivery and I have found what the company is working on from the 2013 annual report seen here it is good stuff.

    Systemic Delivery
    Systemic delivery occurs when a drug accesses the targeted tissue through the circulatory system. In some
    cases, such as in targeting a treatment to the liver, the optimal route of delivery may be by a systemic route. We
    have developed a portfolio of systemic delivery solutions utilizing our RNAi therapeutic platforms. One novel
    approach involves the use of sd-rxRNA compounds. The self-delivering technology introduces properties
    required for in vivo efficacy such as cell and tissue penetration, reduced blood clearance and improved
    distribution properties. Systemic delivery of these sd-rxRNAs to mice has resulted in gene-specific inhibition in
    the liver with no additional delivery vehicle required, albeit at high concentrations. A proof-of-concept
    preclinical study using rxRNA® in conjunction with a standard lipid-based delivery vehicle has enabled us to
    demonstrate gene-specific inhibition in liver at much lower doses in a mouse model after intravenous, systemic
    delivery. While delivery of RNAi to the liver may be critical for the treatment of many diseases, additional target
    tissues that are potentially accessible using rxRNA® compounds by systemic delivery include kidney, fat, heart,
    lung, bone marrow, sites of inflammation, tumors and vascular end

    Sentiment: Strong Buy

  • Reply to

    Email from Tamara for RXII

    by biotechpicklist Jul 25, 2014 8:23 PM
    biotechpicklist biotechpicklist Jul 26, 2014 6:02 AM Flag

    Under EMA (Europe Medical Agency law - think of it as Europe's FDA) an investigational drug can be sold prior to marketing approval if it meets an unmet medical need with a problem/disease with very limited or bad therapies. For scarring Europe and USA have limited options, for instance the FDA has approved " 0 " products for many types of scars.

    Ethicor has a license under Europe law to sell RXI-109 prior to marketing approval. Both Ethicor and RXII split the profit 50/50 for any sold product. The downside is that it can't be marketed in tv ads, magazines etc. But doctors purchase from Ethicor website the stuff they need to help their patients. Ethicor is a specials pharmaceutical company that sales multiple drugs prior to actual FDA/EMA approval. Only Europe has this law to allow investigational drugs to be sold prior to actual marketing approval. The FDA does not allow this!

    RXII made a good deal because under the deal once RXI-109 is approved in Europe/US etc. RXII retains back the entire rights for RXI-109. About next ER I was hoping that RXII would include how much sales they have made by selling some RXI-109 in Europe

    Sentiment: Strong Buy

  • Reply to

    Adam F the moron leading more shorts to ruin

    by jrzbiz Jul 25, 2014 2:37 PM
    biotechpicklist biotechpicklist Jul 25, 2014 9:13 PM Flag

    First with ARNA saying it would be FDA approved, INO saying it would fail results, MNKD etc. I could go on forever lol. He is a political science major he has no medical knowledge whatsoever lol. that's like taking health Advice for yourself from an Artist.

    Sentiment: Strong Buy

  • biotechpicklist biotechpicklist Jul 25, 2014 9:10 PM Flag

    I think it's possible plus they did double the dosage to 4 mg/kg compared to the first cohort. So we shall see if doubling dosage gives increased efficacy.

    Sentiment: Strong Buy

  • biotechpicklist biotechpicklist Jul 25, 2014 9:09 PM Flag

    Both of you are right. Some companies release early with press releases and others do it in the morning before the conference call. Celldex had positive results with its breast cancer drug and said the results in a conference call. Each company has their own way of doing good/bad news you can't hypothesize one way or the other.

    Sentiment: Strong Buy

AMBS
0.1834-0.0101(-5.22%)Jul 30 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.